AURINIA PHARMACEUTICALS INC.

(AUPH)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
8.270 USD   -1.19%
08/08SVB Financial Adjusts Aurinia Pharmaceuticals Price Target to $17 From $22, Maintains Outperform Rating
MT
08/05Oppenheimer Adjusts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains Outperform Rating
MT
08/05RBC Cuts Price Target on Aurinia Pharmaceuticals to $18 From $22, Citing Potential Scenarios for '036 Patent; Outperform, Speculative Risk Kept
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/02/2022 08/03/2022 08/04/2022 08/05/2022 08/08/2022 Date
8.46(c) 8.5(c) 8.52(c) 8.37(c) 8.27(c) Last
1 474 435 2 010 409 7 845 255 3 766 988 3 166 986 Volume
+3.93% +0.47% +0.24% -1.76% -1.19% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 138 M - -
Net income 2022 -125 M - -
Net cash position 2022 362 M - -
P/E ratio 2022 -9,45x
Yield 2022 -
Sales 2023 229 M - -
Net income 2023 -36,3 M - -
Net cash position 2023 300 M - -
P/E ratio 2023 -32,6x
Yield 2023 -
Capitalization 1 173 M 1 173 M -
EV / Sales 2022 5,87x
EV / Sales 2023 3,82x
Nbr of Employees 300
Free-Float 93,6%
More Financials
Company
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support... 
More about the company
Ratings of Aurinia Pharmaceuticals Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about AURINIA PHARMACEUTICALS INC.
08/08SVB Financial Adjusts Aurinia Pharmaceuticals Price Target to $17 From $22, Maintains O..
MT
08/05Oppenheimer Adjusts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains ..
MT
08/05RBC Cuts Price Target on Aurinia Pharmaceuticals to $18 From $22, Citing Potential Scen..
MT
08/04TRANSCRIPT : Aurinia Pharmaceuticals Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04AURINIA : Q2 Earnings Snapshot
AQ
08/04AURINIA PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Conditi..
AQ
08/04AURINIA PHARMACEUTICALS : REPORTS SECOND QUARTER AND SIX MONTHS 2022 FINANCIAL AND OPERATI..
PU
08/04Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
BU
08/04Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Mo..
CI
08/02Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
08/01Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
07/26Aurinia Pharmaceuticals Issues Notice on IPR Review Related to Lupkynis Patent
DJ
07/26Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
BU
07/25Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Result..
BU
07/25Aurinia Announces Positive CHMP Opinion for LUPKYNIS (voclosporin) for the Treatment of..
AQ
More news
News in other languages on AURINIA PHARMACEUTICALS INC.
08/04Aurinia Pharmaceuticals Inc. annonce ses résultats pour le deuxième trimestre et les si..
07/22MISE À JOUR SECTORIELLE : Les actions du secteur de la santé sont en hausse vendredi avant..
07/22Aurinia obtient un avis positif du CHMP pour le traitement du lupus néphrétique actif
07/22Aurinia Pharmaceuticals Inc. annonce un avis positif du CHMP pour Lupkynis« (Voclospori..
07/15Aurinia Pharmaceuticals nomme un nouveau directeur commercial après le départ de Colao ..
More news
Analyst Recommendations on AURINIA PHARMACEUTICALS INC.
More recommendations
Chart AURINIA PHARMACEUTICALS INC.
Duration : Period :
Aurinia Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AURINIA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 8,27 $
Average target price 21,79 $
Spread / Average Target 163%
EPS Revisions
Managers and Directors
Peter S. Greenleaf President, Chief Executive Officer & Director
Joseph M. Miller Chief Financial Officer
George M. Milne Chairman
Robert B. Huizinga Executive Vice President-Research
Neil Solomons Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AURINIA PHARMACEUTICALS INC.-63.84%1 173
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-20.64%41 093